Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
Public ClinicalTrials.gov record NCT02207920. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants
Study identification
- NCT ID
- NCT02207920
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Enrollment
- 104 participants
Conditions and interventions
Conditions
Interventions
- AIDSVAX B/E Vaccine Biological
- DNA-HIV-PT123 Vaccine Biological
- Placebo for AIDSVAX B/E Biological
- Placebo for DNA-HIV-PT123 Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 50 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2014
- Primary completion
- Nov 30, 2015
- Completion
- Nov 30, 2015
- Last update posted
- Oct 14, 2021
2014 – 2015
United States locations
- U.S. sites
- 7
- U.S. states
- 5
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Bridge HIV CRS | San Francisco | California | 94143 | — |
| Columbia P&S CRS | New York | New York | 10032-3732 | — |
| New York Blood Center CRS | New York | New York | 10065 | — |
| University of Rochester Vaccines to Prevent HIV Infection CRS | Rochester | New York | 14642 | — |
| Penn Prevention CRS | Philadelphia | Pennsylvania | 19104 | — |
| Vanderbilt Vaccine (VV) CRS | Nashville | Tennessee | 37232-2582 | — |
| Seattle Vaccine and Prevention CRS | Seattle | Washington | 98109-1024 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02207920, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 14, 2021 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02207920 live on ClinicalTrials.gov.